This study was designed to compare thymidylate synthase (TS) genotype, mRNA and protein levels in primary colorectal adenocarcinoma, and to examine the correlation between microsatellite instability (MSI) and TS expression. The TS genotype of 68 patients with colorectal cancer was determined by polymerase chain reaction (PCR) and restriction fragment length polymorphism analysis in peripheral blood mononuclear cells and tumour tissue. The TS mRNA levels in tumour tissue were measured by reversetranscription PCR, and TS protein levels and MSI status were assessed using immunohistochemistry.
Introduction
Thymidylate synthase (TS) plays a central role in the biosynthesis of thymidylate, an essential precursor for DNA synthesis, and is the target enzyme for 5-fluorouracil (5-FU) and other fluoropyrimidine-based therapies as well as folate-based TS inhibitors and nonclassical TS inhibitors. 1 Now, 50 years after its discovery, 5-FU remains an important component of many standard chemotherapies for solid tumours, such as in the multimodal therapy of colorectal cancer. 2 -4 Only a fraction of treated patients seem to benefit from 5-FU and most experience adverse effects. Thus, it would be useful to have a molecular marker that allows the selection of that minority of patients who are likely to benefit from MH Kristensen, M Weidinger, M Bzorek et al. TS gene variants, RNA and protein levels in colorectal cancer treatment with 5-FU, while sparing those unlikely to benefit.
High levels of TS protein or mRNA in primary colorectal cancer have been associated with reduced responsiveness to 5-FU, and with adverse outcomes, in several studies of patients with metastatic disease. 5 -9 Contradictory data have been presented in other studies. 10 -13 In the adjuvant setting, the relationship between TS levels and patient survival rates after 5-FU-based treatment is less well established. 9,10, 14 -22 Heterogeneous results between studies may relate to the heterogeneity of material, misclassification of outcome and/or criteria used to assign TS status.
Knowledge of the regulation of TS gene expression would be of considerable value in understanding the mechanism of 5-FU sensitivity. Tumours with microsatellite instability (MSI), which are hypothesized to be resistant to 5-FU, have been shown to have increased TS gene expression. 23, 24 Furthermore, three gene variants in the untranslated region (UTR) of the TS gene have been shown to affect transcriptional activity. The TS gene contains a unique 28-base-pair (bp) tandem repeat sequence (called 'R') in the enhancer region of TS (TSER). Three common TSER genotypes (2R/2R, 2R/3R and 3R/3R) have been identified in Caucasian populations. 25 More rarely, one, four, five and nine copies have also been reported, predominantly in Asian and African populations. 26 -29 These tandem repeat sequences appear to function as an enhancer of transcription and translation. 25,30 -32 A common single nucleotide polymorphism (SNP) (G > C) has been identified at the 12th nucleotide of the second repeat in the 3R allele, leading to a triallelic locus (2R, 3RC and 3RG). This SNP abolishes binding of upstream stimulatory factor 1 (USF-1), leading to decreased transcriptional activity. 33, 34 Thus, patients can be classified as having 'high' TS (2R/3RG, 3RG/3RC, 3RG/3RG) or 'low' TS (2R/2R, 3RC/3RC, 2R/3RC) gene expression in accordance with the combination of this SNP and the TS genotype. 32, 34 A third polymorphism has been implicated in the regulation of TS gene expression at a post-transcriptional level. The 6-bp deletion(del)/insertion(ins) (position TS1494, del6 or ins6) in the 3′-UTR has been associated with decreased mRNA stability in vitro and lower TS expression in vivo. 30, 35 Whether the polymorphism affects TS expression on a transcriptional or translational level remains to be resolved. 30, 32, 36 The discovery of TS gene variants that might be determinants of tumour response is of considerable interest, as prediction of response could potentially be achieved by analysis of readily available normal tissue, e.g. peripheral blood cells. This expectation is based on the assumption that the genotype in normal tissue is identical to that in cancer tissue. Because allelic losses at chromosome 18 (the TS gene is localized here) are highly prevalent, tumour genotyping rather than germ line analysis may be more informative. 27, 37, 38 There is no consensus on the relationship between gene variants in the TS genotype, mRNA and protein levels 22,25,32,39 -41 and, at present, there is no general agreement on the best way to assess TS status. To the authors' knowledge, the present study represents the first time that the relationship between TS genotype and the level of TS mRNA/protein and MSI status has been evaluated.
Patients and methods

PATIENTS AND SAMPLES
Chemotherapy-naïve patients with colorectal cancer who underwent surgery at Naestved Hospital, Naestved, Denmark between 2004 and 2006 were enrolled sequentially into the TS gene variants, RNA and protein levels in colorectal cancer study. Patients were included if they had a tumour that was operable and confirmed as colorectal cancer using histopathology. Tumour specimens and surrounding normal colon tissue situated distal and proximal to the tumour were obtained from the patients during surgery. Patients' tumours were classified according to the tumour, node, metastasis (TNM) staging system of the American Joint Committee on Cancer. 42 Any patient receiving pre-operative chemotherapy was excluded from the study. Written or verbal informed consent was received from all participants and the protocol was approved by the Danish National Committee on Biomedical Research Ethics.
Immediately after surgery, specimens were transferred to the Pathology Department at Naestved Hospital and routinely processed. Fresh frozen tissue and formalin-fixed tissue were used. Formalin-fixed paraffin-embedded sections for DNA and RNA analysis were selected from blocks containing normal tissue and blocks containing predominantly tumour tissue with as little admixture of normal tissue, necrotic tissue and lymphocytes as possible. A blood sample was drawn from each patient at the time of surgery.
DNA EXTRACTION
Germ line DNA was extracted from whole blood cells by a modified version of the alkaline extraction method. 43 DNA was extracted from formalin-fixed paraffinembedded tissue using the DNeasy ® Blood and Tissue kit (Qiagen Inc., Valencia, CA, USA), according to the manufacturer's recommendations.
TS GENOTYPING
The TS UTR regions were amplified by polymerase chain reaction (PCR) using the primers 5′-GGGACGGCCGCGGGAAAAGG-3′ (forward) and 5′-GCAGGCTCGGCCGGTG TCCGT-3′ (reverse). 44 The G > C SNP was analysed by PCR-restriction fragment length polymorphism (PCR-RFLP) as described previously. 34 A 15 µl aliquot of the PCR reaction was digested with HaeIII. The presence of an additional 94-bp fragment depicted the C allele. The TS 3′-UTR genotype was determined by PCR-RFLP using the following primer pair: 5′-CACAAGCT ATTTTTGGAAAATTT-3′ (forward) and 5′-GC AGGCTCGGCCGGTGTCCGT-3′ (reverse). 35 Two alleles (6-bp ins/6-bp del) were identified after DraI digestion. Visualization was carried out by 2% agarose gel electrophoresis and ethidium bromide staining.
LOSS OF HETEROZYGOSITY ANALYSIS
Loss of heterozygosity at the TS locus was assessed by analysing heterozygous patients for any of the three intragenic gene variants and was defined as the loss of intensity observed by naked-eye inspection in any of the alleles analysed using paired normal and tumour tissue.
RNA ISOLATION AND cDNA SYNTHESIS
Total RNA was isolated from fresh frozen tissue and from formalin-fixed paraffin-embedded tissue using the RecoverAll™ total nucleic acid isolation kit (Applied Biosystems, Foster City, CA, USA). The purity and amount of total RNA were estimated spectrophotometrically by measuring the absorbance at 260 and 280 nm. RNA was reverse-transcribed by the MultiScribe™ Moloney Murine Leukaemia Virus (MuLV) reverse transcriptase high capacity cDNA reverse transcription (RT) kit with random primers (Applied Biosystems).
QUANTITATIVE RT-PCR
Levels of TS mRNA were measured by realtime RT-PCR (Real-Time PCR Diagnostic TS gene variants, RNA and protein levels in colorectal cancer System; Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. The primer sequences and cycling conditions were as described by Sasaki et al. 45 The RT-PCR was performed using a LightCycler ® FastStart DNA Master PLUS SYBR ® Green I kit (Roche Diagnostics). Gene expression (relative mRNA level) was expressed as the ratio between TS and an internal reference gene (glyceraldehyde-3phosphate dehydrogenase [GAPDH]), analysed using LightCycler ® relative quantification software (Roche Diagnostics).
IMMUNOHISTOCHEMISTRY
Immunohistochemistry was performed according to a previously published method 46 with minor modifications. The slides were incubated with the primary antibodies to TS (TS106; Dako, Glostrup, Denmark) diluted 1:300 in 1% bovine serum albumin (Sigma-Aldrich, St Louis, MO, USA) in 0.05 mM Trisbuffered saline (TBS), pH 7.6, for 30 min at room temperature. After three washes in this buffer, the reactions were detected using a SuperSensitive™ Polymer horseradish peroxidise (HRP) detection system (BioGenex, San Ramon, CA, USA) and visualized using ImmPACT™ diaminobenzidine (DAB) substrate (Vector Laboratories, Burlingame, CA, USA), following the manufacturers' recommendations.
Negative and positive control slides were included in the staining run. The negative control consisted of replacing primary antibody with 0.05 mM TBS. The positive control was a section of tumour known to stain heavily for TS. Reactive lymphocytes served as internal controls. Staining intensity and the percentage of stained tumour cells were considered in the staining assessment as described by Lindebjerg et al. 47 Intensity was graded on a semiquantitative scale from 0 to 3 (0, no staining; 1, weak staining intensity; 2, strong staining intensity; and 3, very strong staining intensity). The extent of staining was graded on a scale from 0 to 4 (0, no staining; 1, staining of 0% -10% of carcinoma cells; 2, staining of 10% -25% of carcinoma cells; 3, staining of 25% -50% of carcinoma cells; and 4, staining of > 50% of carcinoma cells). A TS score, as a measure of the extent and intensity of immunohistochemical staining for TS protein, was calculated by multiplying the grades for staining intensity and staining extent. The predominant immunohisto chemical reaction pattern was recorded (pattern 1, diffuse weak staining or no staining; pattern 2, weak staining with interspersed strong-stained carcinoma cells; and pattern 3, diffuse strong staining of the carcinoma cells). The immunostaining pattern was also classified as 'cytoplasmic' or 'nuclear' (nuclear with or without cytoplasmic expression). All slides were examined by two experienced observers (M Bzorek [author] and M Mohammadi [see Acknowledgements]) blinded to marker status. In cases of disagreement, the score was determined by consensus.
MICROSATELLITE INSTABILITY
Immunohistochemical staining was performed with antibodies against MLH1 (BD Clone G168-15; 1:250 dilution), MSH2 (BD Clone 27; 1:100), PMS2 (BD Clone A16-4; 1:250) and MSH6 (BD Clone 44; 1:600) (all from BD Bioscience, San Jose, CA, USA). Slides were incubated with primary antibodies for 30 min at room temperature and, after three washes in 0.05 mM TBS, pH 7.6, the reactions were detected using the SuperSensitive™ Polymer HRP detection system (Biogenex) and visualized by Vector ® NovaRED™ (Vector Laboratories) following the manufacturer's instructions. The reaction in proliferating normal cells within the tumour section served as an internal control. TS gene variants, RNA and protein levels in colorectal cancer
STATISTICAL ANALYSIS
All data were analysed using the SPSS ® statistical package, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Interobserver reproducibility for the immunohistochemical staining assessments was tested by Cohen's κ-statistic. Analyses involving mRNA and genotypes were carried out on the following subsets of patients: (i) two subgroups selected on the basis of having high or low levels of TS mRNA (cutoff 0.79); and (ii) the combination of SNP and TSER ('low' 2R/2R, 3RC/3RC, 2R/3RC and 'high' 2R/3RG, 3RG/3RC, 3RG/3RG). The Kruskal-Wallis test was used to assess the correlation between TS mRNA and genotypes.
Correlation between TS immunohistochemical scores and TS gene variants was tested by the Mann-Whitney two-sample rank test. The Spearman rank order correlation between the TS immunohistochemical score and TS mRNA was also calculated. The correlation of TS gene expression with clinical and pathological characteristics was analysed using the Spearman test (age) and the Wilcoxon rank sum test (sex). The correlation between the different TS gene variants and pathological characteristics was analysed using Fisher's exact test for sex and stage and the Kruskal-Wallis test for age. A P-value < 0.05 was considered to be statistically significant.
Results
CLINICAL AND PATHOLOGICAL CHARACTERISTICS
The main clinical and pathological characteristics of the patients are presented in Table 1 . The case series comprised 68 patients with colorectal cancer: 25 females and 43 males with a mean ± SD age of 70 ± 9.7 years (range 42 -91 years). The site of the primary tumour was colonic in 46 cases and rectal in 22 cases (primary stage I, five patients; stage II, 29 patients; stage III, 27 patients; and stage IV, seven patients). All 68 patients had adenocarcinomas.
TS GENOTYPE
The genotype frequencies of the TS tandem repeat polymorphism were 24% (2R/2R), 61% (2R/3R) and 15% (3R/3R). The frequency of each TS SNP genotype was 24% (2R/2R), 12% (3RC/3RC), 36% (2R/3RC), 24% (2R/3RG) and 4% (3RG/3RC). The distribution of the TS 3′-UTR genotypes was 12% 6-bp del/6-bp del, 38% 6-bp ins/6-bp del and 50% 6-bp ins/6-bp ins, respectively. The distribution of genetic variants followed the Hardy-Weinberg equilibrium. Homozygous tumour tissue with a matched heterozygous normal tissue and blood sample was found in seven of the 41 heterozygous patients (17%), and they were classified as loss of heterozygosity cases. Due to their small number, they were not included in subsequent analyses. between tumours was detected, while more homogenous TS expression was observed in normal cells. The quantification of TS mRNA from fresh frozen tissue (n = 20) is shown in Fig. 1 . Significantly higher levels of TS mRNA were found in tumour tissue compared with corresponding normal tissue (P = 0.001). The TS/GAPDH ratios from the formalin-fixed tissue were lower than those from fresh frozen tissue, but the differences in TS mRNA between tumour tissue and normal tissue were the same. Marked interindividual variation in TS mRNA levels in the 68 colorectal samples was observed: TS/GAPDH ratios for mRNA in formalin-fixed tissue varied between 0 and 5.07 (> 100 fold), with a mean value of 0.79. This value was used to discriminate between patients with high (≥ 0.79, n = 20) and low (< 0.79, n = 41) TS mRNA levels.
TS MRNA LEVELS
TS PROTEIN LEVELS
Immunohistochemical staining for TS protein in the primary colorectal tumour specimens showed a predominantly granular cytoplasmic staining pattern in the tubular and cribriform glands of the colorectal cancers (Fig. 2 ). Normal colon tissue showed fairly weak positive staining, but to a much lower extent than that observed in the tumour cells. The distribution of TS showed a distinct pattern of spatial polarity within the crypts of the normal mucosa. Of the 68 tumour samples studied, a median TS score of 5 (range 0 -12) was found (TS score [high] > 5, n = 31; TS score [low] < 5, n = 30). Heterogeneity of TS immunostaining was observed both within individual tumours and between different tumours. In most cases, two or three reaction patterns were present within the same section. The interobserver reproducibility of immunohistochemical scoring yielded a κvalue of 0.79. The TS was assessed as exclusively cytoplasmic in two positive tumours (3%) and as nuclear and cytoplasmic in 59 positive tumours (97%).
CORRELATION BETWEEN GENOTYPE, MRNA AND PROTEIN EXPRESSION
No significant difference in TS mRNA levels Tumour tissue with loss of heterozygosity (n = 7) was not included. a Expressed as the ratio between TS and an internal reference gene (glyceraldehyde-3-phosphate dehydrogenase). b TS score is a measure of the extent and intensity of immunohistochemical staining for TS protein, calculated as staining intensity × staining extent, where staining intensity is: 0, none; 1, weak; 2, strong; and 3, very strong, and staining extent is: 0, none; 1, staining of 0% -10% of carcinoma cells; 2, staining of 10% -25% of carcinoma cells; 3, staining of 25% -50% of carcinoma cells; and 4, staining of > 50% of carcinoma cells). c P = 0.01 vs 2R/3R and P = 0.02 vs 2R/2R. d P = 0.01 vs 2R/3R and P = 0.003 vs 2R/2R.
490
MH Kristensen, M Weidinger, M Bzorek et al. TS gene variants, RNA and protein levels in colorectal cancer
was found between the patients of TS genotypes 2R/2R and 2R/3R (mean ± SD TS/GAPDH ratio 0.63 ± 0.04 versus 0.65 ± 0.11) ( Table 2 ). Patients with the TS genotype 3R/3R were found to have significantly increased TS gene expression (mean ± SD TS/GAPDH ratio 1.94 ± 0.09) compared with the 2R/3R patients (P = 0.01) and 2R/2R (P = 0.02) patients.
Patients with the 3R/3R genotype were found to have significantly higher TS protein levels, as measured by the TS score (mean ± SD 8.8 ± 1.3), compared with patients with the 2R/2R (P = 0.003) and 2R/3R genotypes (P = 0.01) ( Table 2 ). No significant difference in TS protein levels was detected between patients with the 2R/2R and 2R/3R genotypes.
TS gene expression (mRNA/protein levels) was compared between the two subgroups, and defined as either 'low' (2R/2R, 3RC/3RC, 2R/3RC; n = 44 [73%]) or 'high' (2R/3RG, 3RG/3RC, There was no significant difference between the 'low' and 'high' groups in either mRNA (mean ± SD TS ratios 1.34 ± 0.05 and 1.45 ± 0.09) or protein (5.8 ± 0.4 and 4.2 ± 1.2) expression, respectively. Individuals homozygous for the 6-bp insertion (6-bp ins/6-bp ins) had significantly higher TS mRNA levels (mean ± SD 1.42 ± 0.17) than individuals who were heterozygous (6-bp ins/6-bp del; mean ± SD 0.73 ± 0.04; P = 0.04) or homozygous for the 6-bp deletion (6-bp del/6-bp del; mean ± SD 0.18 ± 0.002; P = 0.003) individuals. No correlation was detected between the 6-bp deletion and protein levels, or between immunohistochemical pattern and TS genotype (results not shown). A strong correlation was found between levels of TS protein and mRNA, as assessed by immunohistochemistry and RT-PCR, when divided according to TS gene expression. Patients in the low TS gene expression group (TS mRNA < 0.79) showed a significantly lower TS protein level (mean ± SD 3.8 ± 0.7) than the high expression group (TS mRNA ≥ 0.79; 7.4 ± 0.9; P = 0.01) ( Table 3) .
No correlation between TS mRNA levels and patient characteristics (age, gender) or tumour characteristics was observed (data not shown).
MSI AND TS GENOTYPE AND EXPRESSION
Seven cases (11%) of MSI were detected and expression of the TS gene was significantly higher in MSI tumours compared with microsatellite stable (MSS) tumours when assessed by immunohistochemistry (mean ± SD TS protein levels of 7.4 ± 0.9 versus 3.8 ± 0.8; P = 0.01) and RT-PCR (mean ± SD TS mRNA levels of 0.97 ± 0.11 versus 0.77 ± 0.09; P = 0.02). All seven MSI tumours were found to be heterozygous or homozygous for the G > C SNP (relative risk [RR] 3.2). No correlation between MSI and TS repeat variants or 3′-UTR genotype was found (data not shown). All seven MSI tumours showed a reaction pattern of ≥ 2 (RR 2.1).
Discussion
The interest in genetic factors that could be predictive for response to 5-FU treatment is increasing as new alternatives to this drug are developed. The possibility of determining TS status from normal tissue, or even from peripheral blood mononuclear cells, has received considerable attention because the latter would represent an easily accessible tissue sample for characterizing the TS status of a patient's tumour. 26 The most common techniques used to assess TS expression are enzyme activity
TABLE 3: Intratumoural thymidylate synthase (TS) scores (protein levels) according to 'high' or 'low' expression of TS mRNA in colorectal tumour tissue
mRNA expression a n TS score (mean ± SD) b 'Low' < 0.79 41 3.8 ± 0.7 'High' ≥ 0.79 20 7.4 ± 0.9 c a Expressed as the ratio between TS and an internal reference gene (glyceraldehyde-3-phosphate dehydrogenase). b TS score is a measure of the extent and intensity of immunohistochemical staining for TS protein, calculated as staining intensity × staining extent, where staining intensity is: 0, none; 1, weak; 2, strong; and 3, very strong, and staining extent is: 0, none; 1, staining of 0% -10% of carcinoma cells; 2, staining of 10% -25% of carcinoma cells; 3, staining of 25% -50% of carcinoma cells; and 4, staining of > 50% of carcinoma cells). c P = 0.01 vs 'low' mRNA expression. TS gene variants, RNA and protein levels in colorectal cancer assay, 48,49 immunohistochemistry 50 and RT-PCR; 51 none of which is ideal. The enzyme activity assay is time-consuming, expensive and difficult to perform. Immunohistochemistry is easier to perform, cell specific and less labour intensive, and seems to be a good alternative to intratumoural TS enzyme activity. 48, 52 The evaluation is, however, only semiquantitative and, as a result, is difficult to standardize. Staining intensity can be influenced by a large variety of factors (antibody concentration, method of antigen retrieval, etc.), making quantitative immunohistochemistry difficult. In contrast to immunohisto chemistry, RT-PCR gives data in the form of numerical expression; PCR technology, however, involves the use of a homogenous solution so is dependent on the amount of non-tumour tissue in the analysed sample and may not truly reflect overall tumour gene expression. Avoiding the contamination of tumour samples by normal tissue is critical if TS expression is significantly different in tumour tissue compared with normal adjacent tissue (as found in the present study). 53 -55 To date, most published studies appear to have used specimens 'as is', i.e. without any particular post-acquisition processing to separate tumour from non-tumour tissue. Tumour tissue is known to be highly heterogeneous and differing expression of molecular markers can be obtained depending on the excision site, making it difficult to identify reliable markers. Substantial interpatient variability was found both in TS mRNA and protein levels in the present study. Contrary to the results obtained by Amatori et al., 56 no correlation was observed in the present study, between TS mRNA levels and patient characteristics (age, gender) or tumour characteristics. Lack of standardization of procedures, homogeneous patient material and validated quality control is, therefore, an inherent problem for biomarker determination.
The discovery of TS gene variants that may be tumour response determinants was of considerable interest as it could make it possible for response prediction to be carried out by analysis of readily available normal tissue, e.g. peripheral blood cells. This expectation was based on the assumption that the genotype in normal tissue would be identical to that in cancer tissue. Research has shown, however, that this assumption is not always true in the case of the TS genotype: a high incidence of loss of heterozygosity has been observed at the TS locus in cancer tissues, which leads to modification of the TS genotype in the tumour compared with heterozygous normal tissue. 57 The frequency of the 2R/2R, 3R/3R and 2R/3R genotypes was 24%, 15% and 61%, respectively, which is consistent with frequencies previously reported for Caucasians. 28, 58, 59 Although four to nine repeats of 'R' in the TS enhancer region have been described, 28,29 no alleles with more than three tandem repeats were observed in the present study. The TS genotypes have been found to be identical in normal and tumour tissue of homozygous individuals, suggesting that the genetic variants are stable through carcinogenesis. In heterozygous samples, however, an imbalance between the 2R and 3R alleles in the tumour DNA has been frequently observed, suggesting loss of heterozygosity at the TS locus. 27 Correlation between the TS genotype in normal tissue (peripheral blood cells and normal colon mucosa) and tumour tissue has been reported in 89% of patients. Only 17% of the heterozygous samples were found to have loss of heterozygosity in the present study, which is considerably less than has been described in the literature. 6, 57, 60 This could be due to a large number of normal cells TS gene variants, RNA and protein levels in colorectal cancer affecting the results.
In accordance with previously published results, 25, 32, 47 significantly lower protein levels were observed in tumours from patients with TS 2R/2R compared with tumours from patients with TS 3R/3R. No statistically significant difference was observed between tumours from patients with TS 2R/2R and 2R/3R. The mechanism of the regulatory effect is not clear. It has been suggested by Marsh et al. 61 that the tandem repeats could form stem loop structures with an inverted repeat sequence located upstream from the enhancer region, thereby allowing more efficient transcription and subsequent translation of the TS gene.
The presence of an additional cis acting genetic variant has been shown to be involved in the control of TS transcriptional activity. 36 This novel polymorphism is represented by a 6-bp deletion starting at position 1496 of the 3′-UTR and its frequency in the present study (50% ins/ins, 38% ins/del and 12% del/del) was in accordance with what has previously been published. 35 Although the presence or absence of the TS 3′-UTR 6-bp nucleotide fragment does not affect the coding of any amino acids, as in the case of the TS 5′-UTR 28-bp sequence repeat polymorphism, the 3′-UTR polymorphism can lead to changes in TS genetic structure, potentially affecting the stability of TS mRNA and affecting its expression. Mandola et al. 35 found that the absence of the TS 3′-UTR 6-bp nucleotide fragment correlated with a reduction in TS mRNA, similar to results from the present study. As with the present study, however, Merkelbach-Bruse et al. 40 challenged the observation by Mandola et al., 35 of there being no relationship between the 6-bp deletion in the 3′-UTR and TS protein level. The possible role of the 6-bp allele on TS expression may be due to combined effects with the 3RG allele. 33 -35 Previous studies have found that the G > C substitution at position 12 within the second tandem repeat directly influences TS levels due to disruption of an E-box binding site for USF within each 28-bp repeat. 34, 53 The transcriptional activity of the TS gene, therefore, seems not to be enhanced by the number of tandem repeats alone, but is dependent upon the extra USF E-box within each one. Accordingly, previous clinical reports have classified patients as 'low' expressers or 'high' expressers. 33, 62, 63 In contrast to the TSER (2R/3R) polymorphism, the reported rates of the SNP genotypes are rather heterogeneous. 33, 34, 56, 62, 63 In contrast to published data 34 no effect of the SNP on TS (mRNA and protein) expression was observed in the present study. The genotype 3RG/3RG, that is expected to confer high TS expression, was completely lacking in the present patient cohort. The cause of this discrepancy is unknown.
Genotype division into 'high' and 'low' TS expressors has produced inconsistent results. For example, Morganti et al. 53 described an effect of the SNP on TS expression, including only 3RG/3RG in the 'high' group, finding no effect of the 3R genotype. The discrepancies on the effect of genotype on TS expression may partly be explained by the fact that correlating genotype in normal tissue with tumour expression necessitates detection of loss of heterozygosity and consideration of additional regulatory factors.
The present study supports the association between TS gene variants and mRNA levels. 30 In a systematic review and metaanalysis of TS expression in colorectal cancer, the median proportion of cases with a high level of TS gene expression was 50% (range 19% -77%), 9 which is in agreement with the present study (mRNA 'high', 33%; protein 'high', 51%). The TS mRNA levels Expression of the TS gene can be controlled by many factors, including E2F1, 64 p53, 65 c-myc, 66 autoregulation, 67 rTS 68 and nuclear factors (NF-TS). 69 Expression of the TS gene has also been shown to be dependent on MSI. For example, the present study, which is in agreement with Ricciardiello et al., 24 Calascibetta et al., 70 and Jensen et al., 71 shows that cancers with MSI have higher levels of TS protein than MSS tumours. To the best of our knowledge, the present study showed for the first time that TS mRNA levels are significantly higher in MSI tumours than in MSS tumours. These findings for TS mRNA, however, were made using a small sample size and the results are in contrast with the findings of Calascibetta et al. 70 This increase in TS gene expression could not be explained by altered TS genotype, although all MSI tumours were heterozygous or homozygous for the SNP, which is in agreement with previously published studies. 72 All MSI tumours had a reaction pattern of 2 or 3, and a correlation between high TS protein levels and a reaction pattern of 3 (diffuse strong staining of the carcinoma cells) was seen; Lindebjerg et al. 47 previously reported a correlation between genotype (3R/3R) and staining pattern (staining pattern 3). A connection between MSI and reaction patterns has not, to the best of our knowledge, been described previously, and the significance and cause of this finding remain unknown.
The limitations concerning tumour heterogeneity and the conventional methods used to determine TS status may be overcome by blood analysis for germ line gene variants, as has been shown in the present study. A possible genetic instability at the TS locus adds a complicating factor to the use of genotypic analysis of TS gene variants in noncancerous tissue for prediction of TS status. These data are important for pharmacogenomic analyses in 5-FU-based chemotherapy. Prospective, large-scale trials are needed to confirm that TS gene variants may be a useful molecular tool for optimizing drug therapy for patients with cancer. 
